Clinical Trials Sponsored by Symvivo Corporation

Total 6469 results

Symvivo Corporation

Completed

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19

COVID-19

Australia
SymBio Pharmaceuticals

Recruiting

Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation

BK Virus Infection | Kidney Transplantation | Nephropathy

Australia, Japan
SymBio Pharmaceuticals

Completed

Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

Lymphoma, B-cell, Diffuse

Japan
SymBio Pharmaceuticals

Completed

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Japan
SymBio Pharmaceuticals

Completed

Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects

Drug Drug Interaction

Japan
SymBio Pharmaceuticals

Completed

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Japan
SymBio Pharmaceuticals

Completed

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan
SymBio Pharmaceuticals

Completed

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Japan
SymBio Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Withdrawn

Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Terminated

Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain

Postoperative Pain

Japan
SymBio Pharmaceuticals

Completed

Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Low-grade B Cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated

Japan
SymBio Pharmaceuticals

Recruiting

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection (ATHENA)

Adenovirus Infection

United States
SymBio Pharmaceuticals

Completed

Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL

Diffuse Large B Cell Lymphoma

Japan
SymBio Pharmaceuticals

Completed

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan
SymBio Pharmaceuticals

Completed

A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Japan
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Japan
SymBio Pharmaceuticals

Completed

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Radiotherapy-induced Nausea and Vomiting (RINV)

Japan
SymBio Pharmaceuticals

Completed

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Follicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, Diffuse

Japan, Korea, Republic of
SymBio Pharmaceuticals

Terminated

Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma

Multiple Myeloma

Japan
GenMont Biotech Incorporation
Biomedical Development Corporation

Completed

the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis (PAR)

Probiotics | Perennial Allergic Rhinitis | Lactobacillus Paracasei GMNL-32 (eN-Lac®)

Taiwan
BioMendics, LLC
Symbio, LLC

Completed

Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants

Wound Healing

United States
Amneal Pharmaceuticals, LLC
Symbio, LLC

Completed

Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)

Uncomplicated Urinary Tract Infections

United States
Sofregen Medical, Inc.
Symbio, LLC

Active, not recruiting

Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler

Nasolabial Fold | Cheek Augmentation

United States
Prollenium Medical Technologies Inc.
Symbio, LLC

Completed

A Multicenter, Open-Label Retreatment Study of the Safety and Effectiveness of PN40082 for Lip Augmentation

Lip Augmentation

United States
Prollenium Medical Technologies Inc.
Symbio, LLC

Terminated

A Multicenter, Double-blind, Randomized, Controlled, Roll-over Retreatment Study of the Safety and Pain Associated With Injections of PN40082, RV001 With Topical Anesthetic or RV001 for Lip Augmentation

Lip Augmentation

United States
Prollenium Medical Technologies Inc.
Symbio, LLC

Completed

Safety and Effectiveness of PN40082 for Lip Augmentation

Lip Augmentation

United States
Boston Scientific Corporation
EKOS Corporation

Withdrawn

Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)

Coronary Artery Disease | Atherosclerosis | Peripheral Artery Disease | Chronic Total Occlusion

United States
Boston Scientific Corporation
EKOS Corporation

Completed

Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System (ACCESS PTS)

Deep Vein Thrombosis | Post-thrombotic Syndrome

United States
Guidant Corporation
Boston Scientific Corporation

Completed

Comparison of Right Ventricular Septal and Right Ventricular Apical Pacing in Patients Receiving a CRT-D Device (SEPTAL-CRT)

Ventricular Fibrillation | Ventricular Tachycardia | Systolic Heart Failure

France, Spain
Rgene Corporation
American BriVision Corporation

Not yet recruiting

Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy

Nonsquamous Nonsmall Cell Neoplasm of Lung

Taiwan
Rgene Corporation
American BriVision Corporation

Not yet recruiting

A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer

Pancreatic Cancer
Boston Scientific Corporation
Guidant Corporation

Terminated

MODULA Modul 7 VRR

Atrial Fibrillation

Germany
Boston Scientific Corporation
EKOS Corporation

Completed

ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism (ULTIMA)

Submassive Pulmonary Embolism

Germany, Switzerland
Boston Scientific Corporation
EKOS Corporation

Completed

Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism (OPTALYSE PE)

Pulmonary Embolism and Thrombosis

United States, United Kingdom
Boston Scientific Corporation
EKOS Corporation

Completed

Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy (SEATTLE II)

Pulmonary Embolism | Acute Pulmonary Embolism | Pulmonary Thromboembolism | Massive Pulmonary Embolism | Sub-massive Pulmonary Embolism

United States
Boston Scientific Corporation
Guidant Corporation

Completed

MODULA Modul 5 BEAT-HF

Heart Failure

Germany
Boston Scientific Corporation
Guidant Corporation

Terminated

MODULA-Study: Modul 10: Benefit of CRT-Therapy in CRT-Patients With QRS-Complex of 120 - 150 Ms

Heart Failure

Germany
Guidant Corporation
Boston Scientific Corporation

Completed

Cognis and Teligen 100 HE and Reliance Quadripolar Defibrillation Lead (4-Site) Field Following (Cogent-4)

Heart Failure | Ventricular Tachycardia, Ventricular Fibrillation

Israel, Denmark
Boston Scientific Corporation
Guidant Corporation

Completed

Septal - Success Rate and Clinical Outcome of Septal Implant of Ventricular Defibrillation Lead

Ventricular Fibrillation | Ventricular Tachycardia

France
Boston Scientific Corporation
Guidant Corporation

Completed

Shockless Implant Evaluation (SIMPLE)

Ventricular Fibrillation | Ventricular Tachycardia

Germany, Spain, Canada, Israel, Netherlands, France, Finland, United Kingdom, Austria, Malaysia, Thailand, Hong Kong, Sweden, Hungary, Australia, Czechia, Norway, Poland
Boston Scientific Corporation
Guidant Corporation

Completed

Feature Assessment Study for Indications Based Programming (FASt-IBP)

Heart Failure | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Flutter

Germany, Spain, Switzerland, China, Austria, Belgium, France, Greece, Latvia, Netherlands, Slovakia
Boston Scientific Corporation
Guidant Corporation

Completed

Japanese Assessment of Indication Based Programming (JASMINE)

Heart Failure | Arrhythmias, Cardiac

Japan
Boston Scientific Corporation
Guidant Corporation

Completed

Quick ICD Study: Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary ? (Quick ICD)

Cardiac Arrest

Germany
Shanghai Antengene Corporation Limited

Terminated

A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors (REACH)

Advanced Solid Tumors

China
Mitsubishi Tanabe Pharma Corporation
Kureha Corporation

Completed

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)

Chronic Kidney Disease

United States, France, Italy, Ukraine, Argentina, Mexico, Poland, Canada, Brazil, Russian Federation, Czechia, Puerto Rico

Clinical Trials Sponsored by Symvivo Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations